Comparison of three parathyroid hormone assays

Area of Science:

• Endocrinology
• Clinical Diagnostics
• Biochemistry

Background:

• Primary hyperparathyroidism (PHPT) is a common endocrine disorder.
• Accurate diagnosis relies on sensitive parathyroid hormone (PTH) assays.
• Distinguishing PHPT from other causes of hypercalcemia, like malignancy, is crucial.

Purpose of the Study:

• To compare the diagnostic efficiency of three different parathyroid hormone (PTH) assays.
• To evaluate the ability of intact PTH, mid-molecule PTH, and an in-house assay (AS 211/32) in diagnosing PHPT.
• To assess assay performance in differentiating PHPT from malignancy-associated hypercalcemia.

Main Methods:

• Evaluation of three PTH assays: intact PTH, mid-molecule PTH, and an in-house assay using antiserum AS 211/32.
• Comparison of assay results in patients with proven primary hyperparathyroidism and healthy subjects.
• Assessment of assay performance in patients with hypercalcemia due to malignancy.

Main Results:

• All three assays showed elevated PTH levels in patients with PHPT.
• The intact and in-house assays detected elevated PTH in 7/9 patients, while the mid-molecule assay detected it in 8/9 patients.
• Intact and in-house assays demonstrated superior ability to distinguish PHPT from malignancy-associated hypercalcemia compared to the mid-molecule assay.

Conclusions:

• Intact PTH and in-house assays offer better diagnostic utility for primary hyperparathyroidism than mid-molecule PTH assays.
• Accurate PTH measurement is essential for differentiating PHPT from other hypercalcemic conditions.
• Assay selection impacts diagnostic accuracy in endocrine disorders.